Market News & Trends
Financial Milestone Achieved in Catalyst’s Subcutaneous Factor IX Program
Catalyst Biosciences, Inc. recently announced it has achieved a financial milestone under its collaboration with ISU Abxis. In June 2017, the first patient and cohort…
Heart Failure Market to Surpass $16 billion by 2026
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK, and Japan is set to grow from…
ProQR’s Drug Candidate Receives Orphan Drug Designation
ProQR Therapeutics N.V. recently announced its investigational drug QRX-411 has received orphan drug designation (ODD) from the US FDA and EMA for the treatment of…
Horizon Discovery Takes Exclusive License for Novel Transposon-Based Gene-Editing Technology Platform
Horizon Discovery Group plc recently announced the completion of licensing agreements with all joint patent holders to provide exclusive worldwide rights to a novel transposon-based…
BeiGene Initiates Pivotal Trial of PD-1 Antibody
BeiGene, Ltd. recently announced that the first patient was dosed in a pivotal clinical trial in China of BGB-A317, an investigational anti-PD-1 antibody, in patients…
Auris Medical Completes Enrollment of Phase 3 Trial
Auris Medical Holding AG recently announced it has completed patient enrollment in the Phase 3 HEALOS clinical trial of AM-111 in idiopathic sudden sensorineural hearing…
Lonza Completes Acquisition of Capsugel, Creating Leading Integrated Solutions Provider
Lonza announced that following the receipt of all required regulatory approvals, it has completed the acquisition of Capsugel S.A. from KKR for $5.5 billion in…
Galapagos NV Announces New Phase 2 Study
“We are pleased with the initiation of this new Phase 2 study with filgotinib," said Dr. Walid Abi-Saab, Chief Medical Officer of Galapagos. "We look…
Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial
Cytokinetics, Inc. recently announced that data relating to patient baseline characteristics and the reasons for patient screen failure, both from the first cohort of the…
Enable Injections Introduces First Multi-Vial/Multi-Syringe Biologics Delivery System
Enable Injections, Inc., the developer of advanced large-volume wearable injectors (LVWI) for subcutaneous delivery of biologics and high-volume drugs, recently announced a new single-,…
Microneedles - A Novel Alternative in Selected Drug Delivery Areas
Microneedles are a novel drug delivery technology that can offer promising advantages as an alternative to classical needle injections and other routes of…
CordenPharma & GE Healthcare Offer Unique End-to-End Solution to Accelerate Oligonucleotide Drug Development
CordenPharma International and GE Healthcare’s Dharmacon business have entered a strategic collaboration to create an end-to-end solution for oligonucleotide-based drug discovery. The collaboration will address…
Argenx Receives Second Preclinical Milestone Payment in Collaboration With LEO Pharma
Argenx recently announced the achievement of the second of two preclinical milestones in connection with its collaboration with LEO Pharma. "Our collaboration with LEO Pharma…
Neos Therapeutics Announces FDA Approval of Extended-Release Orally Disintegrating Tablets
Neos Therapeutics, Inc. recently announced that the US FDA approved Cotempla XR-ODT, the first and only methylphenidate extended-release orally disintegrating tablet for the treatment of…
ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis
ARCA biopharma, Inc. recently announced database lock for the GENETIC-AF Phase 2B interim efficacy analysis, to be conducted by the trial Data Safety Monitoring Board…
Otonomy Announces Successful End-of-Phase 2 Review by FDA
Otonomy, Inc. recently announced that it it has successfully completed an End-of-Phase 2 review with the US FDA for OTIPRIO (ciprofloxacin otic suspension) in the…
Amyris Partners With Queensland on Biofutures Acceleration Program
Amyris, Inc. and the Government of Queensland, Australia, recently announced the next step in their plans to develop a leading industrial biotechnology hub in Southeast…
Glenmark Pharmaceuticals Licenses Small Molecule Oncology Compound
Glenmark Pharmaceuticals recently announced it entered into a licensing agreement with Boston-based APC Therapeutics Inc. for exclusive rights to a small molecule oncology compound based…
Nobilis Therapeutics Receives Patent Covering Treatment of Psychiatric Disorders With Noble Gases
Nobilis Therapeutics recently announced that the patent that it had exclusively licensed from Partners HealthCare/McLean Hospital (an affiliate of Harvard University) has received a notice…
Rentschler Biotechnologie & Rentschler Fill Solutions Announce Strategic Partnership
Rentschler Biotechnologie GmbH and Rentschler Fill Solutions GmbH recently announced a strategic partnership to provide new state-of-the-art fill and finish facilities and one-stop solutions for…
